Skip to main content

Advertisement

SpringerLink
Log in

Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report

  • Case Report - Tumor - Meningioma
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. Nomegestrol acetate (NOMAC) is a widely used progestin-like drug that could be suggested as an alternative for patients taking CPA. We report a case of CPA-related meningioma for which relay from CPA to NOMAC led to further tumor growth and cessation of NOMAC-induced tumor shrinkage. We suggest NOMAC can have a similar effect than CPA on meningiomas. The use of NOMAC as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC in such instances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gil M, Oliva B, Timoner J, Macia MA, Bryant V, de Abajo FJ (2011) Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study. Br J Clin Pharmacol 72:965–968

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Goncalves AM, Page P, Domigo V, Meder JF, Oppenheim C (2010) Abrupt regression of a meningioma after discontinuation of cyproterone treatment. AJNR Am J Neuroradiol 31:1504–1505

    Article  CAS  PubMed  Google Scholar 

  3. Bernat AL, Oyama K, Hamdi S, Mandonnet E, Vexiau D, Pocard M, George B, Froelich S (2015) Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir 157:1741–1746

    Article  PubMed  Google Scholar 

  4. Huang Q, Chen X, Zhu Y, Cao L, Riviere JE (2015) Pharmacokinetics, tissue distribution, and excretion of nomegestrol acetate in female rats. Eur J Drug Metab Pharmacokinet 40:435–442

    Article  CAS  PubMed  Google Scholar 

  5. Yang LP, Plosker GL (2012) Nomegestrol acetate/estradiol: in oral contraception. Drugs 72:1917–1928

    Article  CAS  PubMed  Google Scholar 

  6. Wiemels J, Wrensch M, Claus EB (2010) Epidemiology and etiology of meningioma. J Neuro-Oncol 99:307–314

    Article  Google Scholar 

  7. O’Shea T, Crowley RK, Farrell M, MacNally S, Govender P, Feeney J, Gibney J, Sherlock M (2016) Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep 2016:16–0054

    PubMed  PubMed Central  Google Scholar 

  8. Heijboer AC, Netelenbos JC, Blankenstein MA (2009) Meningioma in untreated congenital adrenal hyperplasia: a relationship? J Neuro-Oncol 92:223–225

    Article  CAS  Google Scholar 

  9. Li X, Zhao J (2009) Intracranial meningiomas of childhood and adolescence: report of 34 cases with follow-up. Childs Nerv Syst 25:1411–1417

    Article  Google Scholar 

  10. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853

    Article  CAS  PubMed  Google Scholar 

  11. Seliger C, Meier CR, Becker C, Jick SS, Proescholdt M, Bogdahn U, Hau P, Leitzmann MF (2017) Metabolic syndrome in relation to risk of meningioma. Oncotarget 8:2284–2292

    Article  PubMed  Google Scholar 

  12. Shao C, Bai LP, Qi ZY, Hui GZ, Wang Z (2014) Overweight, obesity and meningioma risk: a meta-analysis. PLoS One 9:e90167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Koper JW, Lamberts SW (1994) Meningiomas, epidermal growth factor and progesterone. Hum Reprod (Oxford, England) 9(Suppl 1):190–194

    Article  Google Scholar 

  14. Guay DR (2009) Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther 31:1–31

    Article  CAS  PubMed  Google Scholar 

  15. Neumann F, Berswordt-Wallrabe RV, Elger W, Steinbeck H, Hahn JD, Kramer M (1970) Aspects of androgen-dependent events as studied by antiandrogens. Recent Prog Horm Res 26:337–410

    CAS  PubMed  Google Scholar 

  16. Froelich S, Dali-Youcef N, Boyer P, Kehrli P, Maitrot D, Auwerx J (2008) Does cyproterone acetate promote multiple meningiomas? 10th European Congress of Endocrinology, vol 16 Berlin, 158

  17. Lello S (2010) Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy. Drugs 70:541–559

    Article  CAS  PubMed  Google Scholar 

  18. Mueck AO, Sitruk-Ware R (2011) Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 76:531–539

    Article  CAS  PubMed  Google Scholar 

  19. Durmaz R, Deliorman S, Isiksoy S, Uyar R, Tel E (1999) Luteinizing hormone releasing hormone increases proliferation of meningioma cells in vitro. Arch Physiol Biochem 107:286–291

    CAS  PubMed  Google Scholar 

  20. Lee KL, Terris MK (2003) Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma. Urology 62:351

    PubMed  Google Scholar 

  21. Cottin V, Vukusic S, Jouanneau E, Lazor R, Cordier J-F (2004) Should patients with lymphangioleiomyomatosis undergo screening for meningioma? Eur Respir J 24:888–889

    Article  CAS  PubMed  Google Scholar 

  22. Raudrant D, Rabe T (2003) Progestogens with antiandrogenic properties. Drugs 63:463–492

    Article  CAS  PubMed  Google Scholar 

  23. Shimizu J, Matsumoto M, Yamazaki E, Yasue M (2008) Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo) 48:227–230

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Hôpital Lariboisière, Paris VII-Diderot University, 2 rue Ambroise Pare, 75475, Paris, France

    Pierre-Olivier Champagne, Thibault Passeri & Sebastien Froelich

  2. Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, 2 rue Ambroise Paré, 75010, Paris, France

    Pierre-Olivier Champagne

Authors
  1. Pierre-Olivier Champagne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thibault Passeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sebastien Froelich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre-Olivier Champagne.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Patient consent

The patient has consented to the submission of the case report for submission to the journal.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Tumor - Meningioma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Champagne, PO., Passeri, T. & Froelich, S. Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. Acta Neurochir 161, 589–592 (2019). https://doi.org/10.1007/s00701-018-03782-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-018-03782-4

Keywords

Search

Navigation